Prof. Paolo Pozzilli

Full Professor of Endocrinology and Metabolic Diseases, Director of the Endocrinology Area at theUniversità Campus Bio-Medico di Roma, where he is Head of the School of Specialization in Endocrinology and Diabetology and of the International Doctoral Research School of Endocrinology and Metabolic Diseases. She is also Professor of Diabetes Research at St. Bartholomew's and the London School of Medicine, Queen Mary, University of London. You have worked for a long time in the field of immunointervention in type 1 diabetes as coordinator of the IMDIAB group of the Universities and Hospitals of Rome. This group writes and manages immune intervention protocols in type 1 diabetes and has published 12 clinical studies in the scientific sector.

Professor Pozzilli has published 395 papers (available on Pubmed) on both type 1 and type 2 diabetes, diabetes complications, new ways of administering insulin and autoimmune thyroid diseases.

Professor Pozzilli is the national coordinator for Italy of several international clinical studies such as TRIGR, ET1DGN, REKORD, DiaPep277, DEFEND 1 and DEFEND 2 and AIDA.

He is currently the European Editor of the journal Diabetes Metabolism Research & Reviews and in the past he was a member of the scientific committee Juvenile Diabetes Research Foundation (USA), as well as many other evaluation committees in the field of diabetes and endocrinology.

Research funding:

2021-2024, PRIN, Local PI for the “Covid-19 and Diabetes” Project

2018-2021 PRIN, National Coordinator for the Project "Pancreatic β-cell identity, glucose sensing and the control of insulin secretion"

01/2015 – 01/2017 Rome Foundation Grant. Evaluation of corneal innervations as a new tool to detect autonomic neuropathy in diabetes

04/2015 – 04/2017 Strategic Research Grant Campus Bio-Medico on Wnt signaling and bone strength in obesity. Co-Investigator

11/2015 – 11/2016 EFSD/JDRF/Lilly European Research Program in Type Diabetes Research. Antibodies to post-translationally modified insulin as biomarker of type 1 diabetes.

05/2015 Study JDRF-IMDIAB entitled “Observational longitudinal study on the natural history of type 1 diabetes: the role of insulin modified by reactive oxidative stress as autoantigen in type 1 diabetes”.

06/2015 – 06/2016 JDRF-Innovative Grant on novel antigen-based therapies for type 1 diabetes: Post-translationally modified insulin as target for therapy in type 1 diabetes.

2013-2015 PRIN Project, National Coordinator of the project on "Juvenile Obesity and cardiovascular risk"

2009-2012 Italian Ministry of University and Technological Research "The new co-morbidities associated with juvenile obesity"

2009-2012 Italian Ministry of Health "Immunological and genetic markers of diabetes"

2004-2012 JDRF/EU/NIH “Trig Project”, Principal Investigator for continental Italy.

2007 – 2011 Scientific coordinator of the project Identification and study of risk factors for the prevention, diagnosis and treatment of maternal and infant morbidity and mortality. Gaslini Institute of Genoa.

National academic qualifications:

2013 Ordinary Member of the Lancisiana Academy

2013 Coordinator of the PhD in Integrative Biomedical Sciences and Bioethics

2012-2010 Coordinator of the Study Center of the Italian Society of Diabetology (SID)

2007 Appointment as the Rector's Delegate for International Relations, Università Campus Bio-Medico di Roma

2003 Appointment as Director of the International PhD in Endocrinology and Metabolic Diseases, Università Campus Bio-Medico di Roma

International Titles:

2000 Appointed “Honorary Professor of Clinical Research (Diabetes)”, St.Bartholomew's and the Royal School of Medicine & Dentistry (University of London)

1985 Appointed "Honorary Senior Lecturer in Medicine" at St. Bartholomew's Medical College (London University).

1982 Appointed "Honorary Lecturer in Medicine" Medical College of St. Bartholomew's Hospital (London University).

Directorate of scientific journals:

Editor in Chief "Diabetes Metabolism Research & Reviews" (Wiley Publisher UK)

Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement From an International Expert Panel.

Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P, Leslie RD. BuzzettiR, et al.

Diabetes. 2020 Oct;69(10):2037-2047. doi:10.2337/dbi20-0017. Epub 2020 Aug 26. Diabetes. 2020. PMID: 32847960 Free PMC article.

Hypoglycaemia and its management in primary care settings.

Ibrahim M, Baker J, Cahn A, Eckel RH, El Sayed NA, Fischl AH, Gaede P, Leslie RD, Pieralice S, Tuccinardi D, Pozzilli P, Richelsen B, Roitman E, Standl E, Toledano Y, Tuomilehto J, Weber SL, Umpierrez GE. Ibrahim M, et al.

Diabetes Metab Res Rev. 2020 Nov;36(8):e3332. doi: 10.1002/dmrr.3332. Epub 2020 May 18. Diabetes Metab Res Rev. 2020. PMID: 32343474 Review.

The reconstructed natural history of type 1 diabetes mellitus.

Pozzilli P, Sir A. Nat Rev Endocrinol. 2019 May;15(5):256-257. doi: 10.1038/s41574-019-0192-8.Nat Rev Endocrinol. 2019. PMID: 30858529 No abstract available.

Impact of obesity on the increasing incidence of type 1 diabetes.

Buzzetti R, Zampetti S, Pozzilli P. Buzzetti R, et al.

Diabetes Obes Metab. 2020 Jul;22(7):1009-1013. doi: 10.1111/dom.14022. Epub 2020 Mar 24.

Clinical characteristics of patients with type 2 diabetes with and without Covid-19: A case control study.

Maddaloni E, D'Onofrio L, Alessandri F, Mignogna C, Leto G, Courage L, Sterpetti S, Pascarella G, Mezzaroma I, Lichtner M, Pozzilli P, Agrò FE, Rocco M, Pugliese F, Mastroianni CM, Buzzetti R; CoViDiab Study group. Maddaloni E, et al.

Diabetes Res Clin Pract. 2020 Nov;169:108454. doi: 10.1016/j.diabres.2020.108454. Epub 2020 Sep 21. Diabetes Res Clin Pract. 2020. PMID: 32971157 Free PMC article.

The SAGE study: Global observational analysis of glycemic control, hypoglycaemia and diabetes management in T1DM.

Renard E, Ikegami H, Daher Vianna AG, Pozzilli P, Brette S, Bosnyak Z, Lauand F, Peters A, Pilorget V, Jurišić-Eržen D, Kesavadev J, Seufert J, Wilmot EG. Renard E, et al.

Diabetes Metab Res Rev. 2021 Oct;37(7):e3430. doi:10.1002/dmrr.3430. Epub 2021 Mar 2. Diabetes Metab Res Rev. 2021. PMID: 33369842 Free PMC article.

Effects of COVID-19 Lockdown on Glucose Control: Continuous Glucose Monitoring Data From People With Diabetes on Intensive Insulin Therapy.

Maddaloni E, Courage L, Pieralice S, Carlone A, Pozzilli P, Buzzetti R.Maddaloni E, et al.

Diabetes Care. 2020 Aug;43(8):e86-e87. doi: 10.2337/dc20-0954. Epub 2020 Jun 5. Diabetes Care. 2020. PMID: 32503838 No abstract available.

Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

Pozzilli P, Bosi E, Cirkel D, Harris J, Leech N, Tinahones FJ, Vantyghem MC, Vlasakakis G, Ziegler AG, Janmohamed S

J Clin Endocrinol Metab. 2020 Jun 1;105(6):dgaa149. doi: 10.1210/clinem/dgaa149.J Clin Endocrinol Metab. 2020. PMID: 32219329 Clinical Trial.

Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of body mass index.

Gentilella R, Sesti G, Vazquez L, Sapin H, Reed V, Romera I, Pozzilli P. Gentilella R.

Diabetes Obes Metab. 2019 Dec;21(12):2660-2666. doi: 10.1111/dom.13853. Epub 2019 Aug 28. Diabetes Obes Metab. 2019. PMID: 31392822 Clinical Trial.

Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomized controlled BANTING study.

Rosenson RS, Daviglus ML, Handelsman Y, Pozzilli P, Bays H, Monsalvo ML, Elliott-Davey M, Somaratne R, Reaven P. Rosenson RS, et al.

Diabetes. 2019 Jun;62(6):948-958. doi: 10.1007/s00125-019-4856-7. Epub 2019 Apr 5. Diabetology. 2019. PMID: 30953107 Free PMC article. Clinical trials.